Rhythm Biosciences Ltd has released a press release.
Exercise of RHYO Options underwritten for $4.5m to $6.0m
Earlier from Rhythm Biosciences
- Trading Halt
- Half-Year Financial Report and Appendix 4D
- Rhythm Bio enters ColoSTAT agreement with 4Cyte Pathology
- ColoSTAT commercial deployment - First physician enrolled